In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth.
DiaMedica Therapeutics Inc (NASDAQ: DMAC) closed the day trading at $8.31 up 1.22% from the previous closing price of $8.21. In other words, the price has increased by $1.22 from its previous closing price. On the day, 1.76 million shares were traded. DMAC stock price reached its highest trading level at $8.47 during the session, while it also had its lowest trading level at $8.0.
Ratios:
For a better understanding of DMAC, let’s look at its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 10.67 and its Current Ratio is at 10.67. In the meantime, Its Debt-to-Equity ratio is 0.01 whereas as Long-Term Debt/Eq ratio is at 0.00.
On October 07, 2024, H.C. Wainwright started tracking the stock assigning a Buy rating and target price of $7.H.C. Wainwright initiated its Buy rating on October 07, 2024, with a $7 target price.
Insider Transactions:
The insider trade also gives investors a glimpse into the future direction of stock prices, which can be beneficial to investors. A recent insider transaction in this stock occurred on Nov 19 ’25 when STAHLBERG JAN bought 240,352 shares for $7.21 per share. The transaction valued at 1,732,361 led to the insider holds 8,375,092 shares of the business.
STAHLBERG JAN bought 208,872 shares of DMAC for $1,547,574 on Nov 21 ’25. The 10% Owner now owns 8,712,390 shares after completing the transaction at $7.41 per share. On Nov 18 ’25, another insider, STAHLBERG JAN, who serves as the 10% Owner of the company, bought 182,882 shares for $6.75 each. As a result, the insider paid 1,234,618 and bolstered with 8,134,740 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, DMAC now has a Market Capitalization of 432763552 and an Enterprise Value of 377711520.
Stock Price History:
The Beta on a monthly basis for DMAC is 1.14, which has changed by 0.2808112 over the last 52 weeks, in comparison to a change of 0.13329959 over the same period for the S&P500. Over the past 52 weeks, DMAC has reached a high of $10.42, while it has fallen to a 52-week low of $3.19. The 50-Day Moving Average of the stock is 12.10%, while the 200-Day Moving Average is calculated to be 52.03%.
Shares Statistics:
Over the past 3-months, DMAC traded about 398.13K shares per day on average, while over the past 10 days, DMAC traded about 494180 shares per day. A total of 52.08M shares are outstanding, with a floating share count of 23.18M. Insiders hold about 55.49% of the company’s shares, while institutions hold 25.00% stake in the company. Shares short for DMAC as of 1764288000 were 5254769 with a Short Ratio of 13.20, compared to 1761868800 on 4119047. Therefore, it implies a Short% of Shares Outstanding of 5254769 and a Short% of Float of 14.510000000000002.
Earnings Estimates
The stock of DiaMedica Therapeutics Inc (DMAC) is currently being evaluated by 4.0 analysts who are actively contributing to its market rating.The consensus estimate for the next quarter is -$0.19, with high estimates of -$0.18 and low estimates of -$0.22.
Analysts are recommending an EPS of between -$0.7 and -$0.74 for the fiscal current year, implying an average EPS of -$0.72. EPS for the following year is -$0.76, with 5.0 analysts recommending between -$0.6 and -$0.9.
